Overview

Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is a Randomized, Double-blind, Vehicle-Controlled, Seamless and Adaptive-designed Phase II/III Study to Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Adult and Adolescent Patients with Mild-to-Moderate Atopic Dermatitis. It will consist of phase II and phase III parts, phase II will be a dose-ranging part and phase III will be a pivotal study part.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Reistone Biopharma Company Limited